Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,720.68
(
0.32%
)
US TECH 100
24,136.00
(
0.50%
)
Dow Jones
47,065.45
(
0.25%
)
Brent Oil
99.55
(
1.27%
)
Bitcoin
74,136.23
(
-0.95%
)
News Focus
News Focus
Post# of 257251
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122790
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 106122

Friday, 11/26/2010 3:28:49 AM

Friday, November 26, 2010 3:28:49 AM

Post# of 257251
FDA review of Cladribine extended to Feb 2011:

http://finance.yahoo.com/news/EMD-Serono-Announces-prnews-1755440006.html?x=0&.v=1

All told, things are not looking good for this MS drug from Merck KGaA. It was rejected outright by the EU in Sep 2010 (#msg-54812455). In the US, Cladribine received an RTF letter in 2009; Merck KGaA resubmitted the NDA in Jun 2010 (#msg-51012919) and surprisingly received a priority-review designation from the FDA. However, the FDA’s new 3-month extension for completing the review effectively nullifies the priory-review status.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Unleash the power of Level 2

Spot liquidity moves with access to US order books.

Sign Up